The most recent clinical trial utilizing CART therapy directed specifically towards CLL-1, either alone or in combination with CD33 as previously mentioned (81), obtained promising outcomes in both adult patients (84) and paediatric R/R AML patients (82, 85), (Table 1). Here, CD33 is linked to acute myeloid leukemia.